1. How to Improve Communication for the Safe Use of Medicines?

   • Priya Bahri
   • Mira Harrison-Woolrych

   Special Article 13 December 2012 Pages: 1073 - 1079

2. Acknowledgement

   Acknowledgments 13 December 2012 Pages: 1081 - 1084

3. Communicating the New Pharmacovigilance Landscape

   • I. Ralph Edwards

   Editorial 13 December 2012 Pages: 1085 - 1089

4. Suspected Herbal Hepatotoxicity

   • Rolf Teschke
   • Johannes Schulze

   Current Opinion 13 December 2012 Pages: 1091 - 1097

   

5. Current Challenges and Controversies in Drug-Induced Liver Injury

   • Alberto Corsini
   • Patricia Ganey
   • Michele Bortolini

   Current Opinion 13 December 2012 Pages: 1099 - 1117

   

6. Balancing the Risks and Benefits of the Use of Over-the-Counter Pain Medications in Children

   • Zeina Bárzaga Arencibia
   • Imti Choonara

   Review Article 13 December 2012 Pages: 1119 - 1125

7. Individual NSAIDs and Upper Gastrointestinal Complications

   • Jordi Castellsague
   • Nuria Riera-Guardia
   • Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project

   Systematic Review Open access 13 December 2012 Pages: 1127 - 1146

   

8. Reasons for and Time to Discontinuation of Rimonabant Therapy

   • Marjolein J. C. Willemen
   • Aukje K. Mantel-Teeuwisse
   • Toine C. G. Egberts

   Original Research Article 13 December 2012 Pages: 1147 - 1158

   

9. Internet Accounts of Serious Adverse Drug Reactions

   • Tehreem F. Butt
   • Anthony R. Cox
   • Robin E. Ferner

   Original Research Article 13 December 2012 Pages: 1159 - 1170

   

10. Global Patterns of Adverse Drug Reactions Over a Decade

    • Lise Aagaard
    • Johanna Strandell
    • Ebba Holme Hansen

    Original Research Article 13 December 2012 Pages: 1171 - 1182

    

11. Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders: A Meta-Analysis

    • Ross J. Baldessarini

    Correspondence 13 December 2012 Pages: 1183 - 1183

12. The Authors’ Reply

    • Emmanuel Stip
    • Hoda Moteshafi

    Correspondence 13 December 2012 Pages: 1183 - 1184

13. Olanzapine in Schizophrenia and Affective Disorders

    • Juan Undurraga
    • Eduard Vieta
    • Francesc Colom

    Correspondence 13 December 2012 Pages: 1185 - 1186

14. The Authors’ Reply

    • Emmanuel Stip
    • Hoda Moteshafi

    Correspondence 13 December 2012 Pages: 1186 - 1186

15. Neuropsychiatric Adverse Events and Oseltamivir for Prophylaxis

    • Mark Jones
    • Rokuro Hama
    • Peter Doshi

    Correspondence 13 December 2012 Pages: 1187 - 1188

    

16. The Authors’ Reply

    • Stephen Toovey

    Correspondence 13 December 2012 Pages: 1188 - 1190

    

17. First Workshop on Computational Methods in Pharmacovigilance held during the Medical Informatics in Europe (MIE) Conference, Pisa, Italy, 29 August 2012

    Abstracts 13 December 2012 Pages: 1191 - 1200